Editas Medicine, Inc.
0IFK.L
London Stock Exchange3.65
USD
+0.15
- -
Editas Medicine, Inc.
0IFK.L
(London Stock Exchange)
Recent
price
3.65
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Editas Medicine, Inc. is a pioneering clinical-stage genetic medicine firm dedicated to harnessing the power of CRISPR technology to develop transformative therapies for individuals afflicted with severe illnesses. The company is actively advancing a proprietary gene editing platform, utilizing both CRISPR/Cas9 and CRISPR/Cas12a systems to precisely modify DNA. In a significant strategic shift, Editas Medicine is now concentrating its efforts on in vivo gene editing, aiming to deliver durable, one-time genomic medicines directly within the body. This revised focus includes programs targeting hematopoietic stem cells and liver for conditions such as sickle cell disease and beta-thalassemia, as well as cardiovascular diseases like hyperlipidemia and atherosclerotic cardiovascular disease. Their pipeline includes EDIT-401, an in vivo gene editing candidate for lowering LDL cholesterol, which has shown promising preclinical data in non-human primates. While the company had previously advanced reni-cel (formerly EDIT-301) for sickle cell disease and transfusion-dependent beta-thalassemia into clinical trials, development for this program was discontinued in December 2024 due to the lack of a commercialization partner. Editas Medicine continues to pursue research collaborations for engineered cell medicines in oncology, notably through partnerships for alpha-beta T-cells with Bristol-Myers Squibb and gamma-delta T-cell medicines with Immatics N.V. The firm also announced a collaboration with Genevant Sciences in October 2024 to combine their CRISPR Cas12a systems with Genevant's LNP technology for in vivo gene editing, targeting two undisclosed indications. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, Editas Medicine generates revenue primarily through strategic collaborations, licensing agreements, and milestone payments, as it does not yet have commercialized products. The company is committed to translating groundbreaking science into treatments with the potential to profoundly impact patient lives.